中国创新药产业经过多年在研发、监管、资本和供应链上的发展,竞争力不断提升的同时,在全球医药交易中的占比也正在迅速提升。据报告显示,2025前三季度中国创新药对外授权总金额已突破1000亿美元。其中,三生制药与辉瑞12.5亿美元首付款的合作、恒瑞医药与GSK达成120亿美元合作都十分引人注目。值得注意的是,随着创新药BD合作的不断增多,更具创新性的合作模式也在不断涌现。12月4日,科伦博泰与...
Source Link中国创新药产业经过多年在研发、监管、资本和供应链上的发展,竞争力不断提升的同时,在全球医药交易中的占比也正在迅速提升。据报告显示,2025前三季度中国创新药对外授权总金额已突破1000亿美元。其中,三生制药与辉瑞12.5亿美元首付款的合作、恒瑞医药与GSK达成120亿美元合作都十分引人注目。值得注意的是,随着创新药BD合作的不断增多,更具创新性的合作模式也在不断涌现。12月4日,科伦博泰与...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.